Analysts at Swiss bank UBS (UBS) remain bullish on pharmaceutical concern Eli Lilly & Co. (LLY).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
UBS has reiterated its Buy rating and $1,050 price target on LLY stock, highlighting the company’s growing dominance in the market for weight-loss medications. The price target set by UBS is 34% higher than where the shares currently trade.
In a note to clients, UBS argued that sales estimates for Eli Lilly’s weight-loss drug Zepbound may surpass market expectations by about 15%, while sales estimates for the diabetes medication Mounjaro are in line with current market projections. Overall, UBS is calling for Eli Lilly’s quarterly sales to exceed expectations by 2% when the company next reports its financial results on August 7.
Other Medications
While weight-loss treatments continue to dominate the conversation around LLY stock, UBS notes that the company has a strong pipeline of other drug candidates, including a medication to treat cardiovascular disease that is now in late stage trials.
Also in late stage clinical trials is Eli Lilly’s weight-loss pill that is expected to receive regulatory approval in 2026 and ultimately replace the injections people take to receive Zepbound. LLY stock has been rangebound in recent months and is up only 2% on the year.
Is LLY Stock a Buy?
The stock of Eli Lilly has a consensus Strong Buy recommendation among 19 Wall Street analysts. That rating is based on 16 Buy, two Hold, and one Sell recommendations issued in the last 12 months. The average LLY price target of $1,006.27 implies 28.27% upside from current levels.
